interferon
lambda
recent
known
studi
role
hepat
c
viru
hcv
infect
clinic
potenti
significantli
hamper
due
poor
express
vitro
studi
report
success
product
mammalian
cell
line
glycoengin
structurebas
approach
introduc
de
novo
nglycosyl
guid
structur
analysi
produc
variant
display
improv
express
potenc
preserv
structur
function
model
structur
signal
complex
analyz
nglycosyl
candid
site
select
receptor
bind
activ
engin
variant
receptormedi
signal
pathway
similar
e
coli
version
antivir
activ
induct
level
interferonstimul
gene
isg
robust
variant
engin
variant
may
develop
clinic
applic
util
basic
research
deciph
immunolog
role
previous
transient
express
wildtyp
mammalian
cell
fail
produc
signific
amount
recombin
interferon
ifn
group
cytokin
serv
first
line
defens
virus
addit
protect
role
viral
infect
interferon
ifn
famili
consist
type
ii
iii
ifn
numer
addit
function
influenc
cellular
growth
immun
surveil
tumor
cell
three
ifn
member
activ
jakstat
pathway
induc
interferonstimul
gene
isg
express
bind
respect
receptor
type
interferon
type
ii
interferon
type
iii
interferon
contrast
type
ii
type
iii
ifn
recent
identifi
play
antivir
function
also
novel
immunomodulatori
function
oncolog
autoimmun
diseas
identifi
comput
base
predict
genom
sequenc
discov
genomewid
associ
studi
gwa
hepat
c
viru
hcv
infect
patient
allel
dinucleotid
genet
variant
upstream
locu
chromosom
creat
function
tt
allel
lead
frameshift
therebi
render
pseudogen
interestingli
hcv
patient
allel
henc
express
respond
poorli
treatment
compar
patient
tt
allel
howev
still
induc
major
hepat
isg
express
chronic
hcv
infect
abl
drive
antivir
respons
virus
merscov
vitro
similar
roferona
hairi
cell
leukemia
avonex
multipl
sclerosi
success
phase
clinic
trial
pegyl
hepat
viru
hdv
infect
highlight
pharmaceut
potenti
famili
suggest
weak
signal
peptid
may
respons
impair
secret
proper
glycosyl
may
requir
secret
although
recombin
purifi
bacteri
express
system
refold
inclus
bodi
lack
glycosyl
may
affect
efficaci
recent
glycoengin
introduc
new
glycosyl
site
alter
glycan
composit
cho
cell
wide
use
produc
improv
therapeut
protein
glycan
moieti
affect
variou
protein
properti
solubl
stabil
vivo
activ
serum
halflif
exampl
improv
halflif
product
obtain
glycoengin
moreov
increas
secret
lipas
cutinas
llama
v
hh
antibodi
macrophag
inhibitori
cytokin
result
addit
singl
nglycosyl
site
therefor
propos
glycoengin
viabl
option
improv
express
level
possibl
alter
properti
studi
use
mutagenesi
introduc
new
potenti
nglycosyl
site
base
model
structur
complex
result
indic
among
sever
variant
three
exhibit
enhanc
product
although
glycosyl
de
novo
moreov
variant
retain
bind
affin
specif
receptor
show
potent
signal
antivir
activ
e
colideriv
human
amino
acid
sequenc
ncbi
access
number
use
swissmodel
homolog
model
three
templat
pdb
code
model
highest
qmeanz
qualit
model
energi
analysisz
score
align
structur
pdb
code
creat
model
cell
cultur
accord
atcc
guidelin
use
within
month
receipt
maintain
suspens
express
medium
co
rpm
agit
cell
apath
maintain
co
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
welgen
gl
glucos
lglutamin
penicillinstreptomycin
welgen
smallinterf
rna
sirna
scrambl
sequenc
obtain
santa
cruz
biotechnolog
transfect
sirna
perform
use
lipofectamin
rnai
max
invitrogen
recombin
obtain
pbl
assay
scienc
recombin
obtain
peprotech
recombin
human
obtain
r
system
gene
encod
human
clone
modifi
contain
ctermin
tag
variant
gener
sitedirect
mutagenesi
quikchang
sitedirect
mutagenesi
kit
agil
use
wildtyp
construct
pcr
templat
primer
sitedirect
mutagenesi
list
supplementari
tabl
express
ctermin
construct
replac
protein
gene
deriv
ge
healthcar
life
scienc
thrombin
cleavag
sequenc
lvprg
introduc
gene
protein
gene
use
pcr
primer
order
remov
protein
wildtyp
variant
contain
protein
transfect
cell
use
expifectamin
transfect
kit
invitrogen
follow
manufactur
protocol
purif
variant
supernat
contain
secret
load
onto
igg
sepharos
resin
ge
healthcar
life
scienc
three
wash
pb
proteinbound
resin
incub
overnight
thrombin
vv
pb
remov
ctermin
protein
tag
elut
variant
subsequ
purifi
gelfiltr
chromatographi
superdex
increas
gl
column
ge
healthcar
life
scienc
equilibr
pb
cell
lyse
ripa
buffer
thermo
fisher
scientif
prepar
total
cell
lysat
ten
microgram
cell
lysat
load
sdspage
gel
prior
immunoblot
antibodi
use
immunoblot
nglycan
remov
use
pngase
f
kit
new
england
biolab
accord
manufactur
instruct
briefli
variant
boil
glycoprotein
denatur
buffer
chill
ice
glycobuff
pngase
f
ad
onto
denatur
protein
mixtur
incub
h
western
blot
analysi
glycopeptid
result
nonspecif
digest
prepar
previous
describ
briefli
variant
incub
pronas
e
h
digest
glycopeptid
enrich
graphit
carbon
solidphas
extract
pgcspe
analyz
nanolcchip
qtof
ms
agil
technolog
lcm
msm
data
process
interpret
previous
describ
use
masshunt
qualit
analysi
softwar
version
agil
technolog
gp
finder
softwar
variant
bind
kinet
measur
biolay
light
interferometri
blitz
system
fortebio
pall
life
scienc
mixtur
agit
rpm
wash
buffer
mm
nacl
mm
trishcl
ph
glycerol
assay
perform
room
temperatur
biotinyl
concentr
mgml
load
onto
surfac
streptavidin
biosensor
fortebio
min
follow
wash
load
biosensor
min
wash
buffer
mm
nacl
mm
trishcl
ph
glycerol
remov
unbound
protein
biosensor
tip
immers
drop
contain
indic
concentr
nm
associ
rate
k
measur
min
interv
sensor
subsequ
immers
wash
buffer
min
measur
dissoci
offrat
k
k
measur
nanomol
calcul
ratio
offrat
onrat
result
data
analyz
fit
ligand
model
global
fit
function
japanes
fulmin
strain
genotyp
hcvcc
produc
describ
previous
dmem
contain
human
serum
use
cultur
cell
order
produc
highli
infecti
hcvcc
hcvcc
infect
quantifi
colorimetr
focusform
assay
describ
previous
cell
infect
hcvcc
multipl
infect
moi
total
rna
isol
taqman
realtim
quantit
pcr
perform
describ
previous
brief
total
rna
isol
geneal
geneal
taqman
gene
express
assay
appli
biosystem
use
determin
mrna
level
target
gene
quantif
intracellular
hcv
rna
copi
perform
describ
previous
result
standard
mrna
level
gapdh
data
present
mean
standard
error
mean
taqman
assay
appli
biosystem
use
studi
gapdh
ifnl
protein
r
system
use
studi
data
experi
cell
line
present
mean
standard
error
mean
unpair
ttest
twotail
mannwhitney
utest
perform
statist
analysi
analys
realtim
quantit
pcr
perform
graphpad
prism
version
p
valu
less
consid
statist
signific
low
affin
wildtyp
receptor
hamper
product
stabl
ternari
complex
therefor
structur
alon
complex
determin
recent
mendoza
et
al
introduc
affinityenhanc
mutat
stabil
interact
elucid
crystal
structur
type
iii
interferon
signal
complex
pdb
code
fig
although
share
sequenc
ident
sequenc
align
suggest
interact
similar
manner
ternari
complex
two
reason
first
amino
acid
famili
critic
bind
wellconserv
fig
second
hydroxyl
group
sever
aromat
residu
form
hydrogen
bond
network
also
well
conserv
therefor
model
structur
use
crystal
structur
fig
structur
align
structur
build
model
fig
interestingli
model
structur
indic
critic
hydrophob
pocket
harbor
hydrophob
residu
well
maintain
surfac
fig
use
model
structur
search
new
nglycosyl
candid
site
base
three
criteria
first
site
outsid
receptor
bind
region
minim
chang
receptorligand
bind
signal
activ
second
expos
solvent
allow
access
oligosaccharyltransferas
ost
catalyz
initi
transfer
glycan
lipidlink
oligosaccharid
onto
substrat
asparagin
third
consensu
sequenc
nxst
x
amino
acid
except
prolin
achiev
singl
point
mutat
minim
structur
distort
caus
mutat
six
candid
site
avail
met
three
criteria
fig
b
name
respect
next
examin
express
level
variant
western
blot
found
two
variant
mutat
mutat
result
enhanc
protein
express
fig
interestingli
show
promin
upshift
sdspage
indic
success
hyperglycosyl
also
check
express
level
doubl
mutant
show
enhanc
protein
express
compar
variant
fig
construct
use
western
blot
hit
discoveri
carri
cterminu
histidin
tag
may
interfer
proper
secret
protein
given
extens
distribut
positivelycharg
amino
acid
therefor
substitut
histidin
tag
protein
tag
purifi
three
variant
use
affin
chromatographi
follow
thrombin
digest
order
remov
protein
tag
subsequ
size
exclus
chromatographi
final
variant
analyz
sdspage
coomassi
blue
stain
reduc
nonreduc
condit
result
band
indic
three
variant
monom
fig
elut
profil
standard
protein
indic
monodispers
peak
correspond
variant
kda
fig
like
overs
elut
due
presenc
nglycosyl
variant
confirm
result
shown
follow
section
identifi
presenc
nglycan
three
variant
treat
pngase
f
compar
size
sdspage
variant
locat
higher
molecular
weight
posit
compar
variant
deglycosyl
pngase
f
howev
molecular
weight
three
variant
decreas
level
indic
presenc
nglycan
variant
statu
posit
nglycosyl
may
slightli
differ
variant
fig
use
mass
spectrometri
determin
exact
posit
nglycan
variant
briefli
purifi
variant
treat
pronas
e
produc
glycopeptid
ultim
determin
glycosyl
site
glycopeptid
separ
analyz
nanolcchip
qtof
ms
lcm
data
indic
mutat
variant
glycosyl
wherea
origin
nglycosyl
site
mutat
fulli
occupi
nglycan
fig
accord
pngase
f
treatment
result
migrat
quickli
either
investig
whether
mutat
addit
glycan
variant
affect
bind
receptor
examin
vitro
bind
affin
variant
biolay
light
interferometri
bli
compar
wt
purifi
e
coli
similar
three
variant
properli
bound
receptor
bind
affin
higher
fig
moreov
variant
slightli
higher
affin
toward
k
nm
k
nm
k
nm
k
nm
bind
affin
similar
k
nm
k
nm
k
nm
k
nm
modif
elicit
mutat
glycosyl
inhibit
interact
specif
receptor
even
stabil
interact
order
determin
whether
mutat
addit
glycan
caption
next
page
fig
stimul
reportedli
lead
assembl
transcript
factor
complex
consist
induc
express
critic
antivir
activ
show
variant
also
induc
express
inhibit
hcv
replic
hcvinfect
cell
fig
interestingli
variant
show
significantli
potent
isg
induct
antivir
activ
highlight
green
cyan
respect
mutat
site
potenti
nglycosyl
label
box
orang
endogen
nglycosyl
site
box
blue
sequenc
conserv
highest
lowest
order
color
red
blue
black
sequenc
obtain
crystal
structur
complex
contain
affinityenhanc
mutat
stabil
interact
c
bind
mode
toward
hydrogen
bond
network
shown
similar
interact
map
base
model
structur
left
surfac
represent
bind
site
within
right
hydrophob
residu
color
orang
grey
hydrophob
pocket
harbor
hydrophob
residu
found
within
prolong
exposur
protein
induc
product
unphosphoryl
consist
without
tyrosin
phosphoryl
express
phosphoryl
diminish
result
upregul
set
gene
maintain
longterm
order
assess
whether
variant
display
similar
function
prolong
treatment
evalu
protein
level
compon
protein
level
equal
upregul
fig
nevertheless
variant
maintain
upregul
robustli
maintain
strongli
upregul
express
compar
variant
fig
previous
shown
induc
express
neg
regul
ifn
signal
assess
effect
glycosyl
function
examin
express
level
upon
treatment
variant
cell
line
significantli
increas
upon
treatment
result
slight
increas
variant
show
compar
activ
fig
protein
express
significantli
increas
treatment
form
fig
howev
mrna
express
slightli
upregul
although
signific
differ
among
fig
result
suggest
structurebas
approach
select
de
novo
glycosyl
maintain
biolog
activ
variant
express
superior
activ
compar
recent
research
use
clinic
therapeut
hinder
inabl
obtain
appreci
amount
protein
purif
bacterialderiv
recombin
refold
still
pose
number
problem
includ
complex
purif
step
lack
glycosyl
endotoxin
contamin
studi
exampl
glycoengin
aid
structur
inform
use
overcom
limit
first
report
success
product
protein
mammalian
cell
line
enhanc
properti
compar
requir
simpler
purif
protocol
sever
possibl
variant
display
enhanc
express
potenc
first
presenc
acid
nglycan
may
stabil
protein
chargebal
sinc
unusu
abund
posit
charg
amino
acid
second
consid
immun
respons
activ
trigger
variant
without
critic
affect
receptor
bind
activ
compar
extra
nglycan
may
extend
halflif
report
therebi
increas
fraction
function
protein
treatment
final
sinc
nglycosyl
eukaryot
cotransl
protein
fold
may
also
affect
nevertheless
mechan
behind
enhanc
express
induc
unmodifi
remain
unansw
specul
may
serv
hydrophob
aggreg
nuclei
interact
nearbi
hydrophob
residu
perhap
allevi
effect
studi
uniqu
abl
success
identifi
viabl
de
novo
nglycosyl
site
structur
elucid
glycopeptid
use
endogen
serin
threonin
asparagin
introduc
glycosyl
modif
minim
mutationinduc
structur
distort
candid
contain
nglycosyl
site
random
locat
also
test
data
shown
addit
modif
express
chang
observ
indic
effici
structureori
approach
howev
glycopeptid
contain
detect
mass
spectrometri
suggest
site
may
remain
unmodifi
accord
recent
cryoem
structur
oligosaccharyltransferas
ost
catalyz
initi
transfer
glycan
lipidlink
oligosaccharid
onto
substrat
asparagin
substrat
bind
catalyt
subunit
requir
structur
flexibl
near
glycosyl
sequenc
substrat
model
suggest
locat
flexibl
loop
elimin
candid
site
part
may
partli
explain
success
glycosyl
contrari
may
physic
access
ost
elucid
structur
may
provid
insight
hypothesi
number
interferon
alreadi
target
drug
develop
due
abil
gener
strong
antivir
antitumor
respons
modul
immun
respons
pegyl
variant
use
cancer
hairi
cell
leukemia
roferon
melanoma
multiferon
aidsrel
kaposi
sarcoma
intron
wellknown
treatment
multipl
sclerosi
number
differ
version
avail
rebif
liquid
form
avonex
lyophil
cinnovex
biogener
betaseron
plegridi
pegyl
similar
also
therapeut
potenti
shown
protect
host
variou
virus
includ
influenza
viru
west
nile
viru
noroviru
rotaviru
interest
test
glycosyl
exert
antivir
activ
host
infect
virus
regard
recent
studi
demonstr
suppress
influenza
viru
without
inflammatori
side
effect
howev
previous
shown
express
function
associ
unrespons
treatment
among
hcvinfect
patient
subsequ
studi
show
longterm
exposur
lead
cellular
unrespons
treatment
upregul
indic
treatment
may
detriment
virusinfect
patient
hand
result
shown
fig
indic
treatment
directli
suppress
hcv
replic
whether
treatment
benefici
detriment
virusinfect
patient
might
determin
durat
treatment
use
follow
treatment
although
much
research
insight
mode
action
requir
understand
effect
benefici
detriment
human
health
engin
variant
util
altern
platform
wildtyp
author
declar
known
compet
financi
interest
person
relationship
could
appear
